IFI-A · Leucoanthocyanidin Enhancement

Specimen SS-F-AST-678 // ASTRINGENCY · IFI-A

Leucoanthocyanidin Enhancement V-PR-B

Vaccinium corymbosum

Blueberry

Tier VLeucoanthocyanidin Enhancement

Target Trait

3.45×

fold-change

Leucodelphinidin accumulation index

Technical Specifications

SKU

SS-F-AST-678

Genomic Edits

8

GC Content

46.9%

Construct Length

4,321 bp

Promoter System

Ubiquitin / T7

Expression System

Protoplast PEG-fusion

Host Strain

PEG-mediated

Receptor Target

Polyphenol-astringency axis

IFI Score

345

Pathway Edits

  • DFR-alt overexpression (3',5'-dihydroxyl-preferring dihydroflavonol 4-reductase allele)
  • F3-5H upregulation for B-ring trihydroxylation toward leucodelphinidin branch
  • ANS-KO (anthocyanidin synthase knockout) to block leucodelphinidin conversion to delphinidin
  • LAR-alt co-expression (alternative LAR allele with leucodelphinidin substrate preference)
  • Protoplast PEG-fusion transient and stable integration protocol
  • Enhanced flux via 5'UTR synthetic leader sequence optimization

Key Interventions

DFR-alt allelic shift for leucodelphinidin reductase substrate preferenceANS-KO anthocyanin branch suppression to channel leucodelphinidin accumulationF3-5H trihydroxylation enhancement for leucodelphinidin precursor supplyPEG-4000 mediated membrane fusion at 37°CVariant B enhanced: iterative codon optimization for host-matched expression

IFI Subscale Profile

IFI Profile

IFI-S
—
IFI-U
—
IFI-B
—
IFI-K
—
IFI-C
—
IFI-P
—
IFI-A
345
IFI-F
—

Use Case

Flagship leucoanthocyanidin ingredient production, premium prodelphinidin precursor manufacturing, pharmaceutical-grade leucodelphinidin standardization. Enhanced variant for premium or research-grade applications requiring peak astringency fidelity.

License

$10049 · Tier V License

Includes full construct sequence, CRISPR guide designs, pathway edit specifications, flux balance analysis, and IFI validation data.

Already purchased?

Back to Astringency · IFI-AAll Modalities